Energy Medecine, Magnetism, Wart
Conditions
Brief summary
Traditionally, healers are willing to look after, two out of three French citizens have already appealed to them at least once during their lives. Many healers in good faith are exercising their magnetism as a "gift" often inherited from elders. Now, they create interest of doctors who do not hesitate in some cases to ensure their cooperation, to implicitly recognize their mysterious talents. Some serious studies have examined these practices: Several studies have been conducted on the influence of biofield therapies in pain, depression and fatigue in cancer disease. The investigators propose a study of the effect of magnetism on the wart disease whose cure is objectively assessable. Sixty-two subjects in total would be included, comparing 2 proportions observed: the proportion of healing in the group treated with a "real" biofield therapist (recognized and affiliated to the National Group for Alternative Medicine in France) to the proportion of healing in the group treated with a "fake" biofield therapist (someone assessed as not having capacity to magnetize). The "fake" biofield therapist, placebo, has been trained to replicate gestures during a training validated by an independent recognized biofield therapist.
Interventions
OTHERTrue Biofield therapy
OTHERFake Biofield therapy
Sponsors
University Hospital, Caen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients with common warts on hands or feet for over at least 3 months are eligible for the study. Patients fulfilling one or more of the following criteria will not be included: lack of informed consent prior to randomization, younger than 18 years or under judicial protection, treated with oral corticotherapy for more than 6 months, immunosuppressed or with history of transplant surgery, undergoing chemotherapy or suspected to have carcinomatous warts, or patients with infected warts, injured warts or already treated within 90 days with chemical processing, medical device, surgery or ever treated with biofield therapy. Subject will be excluded from the study if its warts was treated by other treatment during protocol. * ulcerated wart * cancerous wart
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disappearance of a common palmar or plantar wart | week 3 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| disappearance of each other wart than the original one 3 weeks after the therapy | week 3 | — |
| Percentage of reduction of each wart will be calculated using mean diameter of each wart at W0 and W3 | week3 | — |
| Disappearance of warts at 6 weeks | week 6 | — |
| Level of belief in biofield therapy of the subject | week 6 | week 0 |
Countries
France
Outcome results
None listed